Announcements Trials
Browse Landscape

Phase

Phase NA 16Phase 2 8Phase 1 5Phase EARLY_PHASE1 2Phase 3 1

Status

Recruiting 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

FAP- Expressing Positive Tumors 1177Lu-EB-FAPI 1

Interventions

Magnetic Resonance Spectroscopy 17Cyclophosphamide 16fludarabine 12Specimen Handling 12Fluorodeoxyglucose F18 7pembrolizumab 6X-Rays 6Nivolumab 6Temozolomide 5Radiotherapy 5Immunotherapy, Adoptive 5lenvatinib 4Paclitaxel 4Leukapheresis 4Immune Checkpoint Inhibitors 4Etoposide 4Cisplatin 4Carboplatin 4ruxolitinib 3fluciclovine F-18 3Tirzepatide 3Surgical Procedures, Operative 3Doxorubicin 3Dasatinib 3Cholecalciferol 3Biopsy 368Ga-FAPI 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tislelizumab 2palbociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Recruiting × Therapeutics × Clear all
NCT06638034 2024-10-15

Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy With 177Lu-FAPI-RGD

Peking Union Medical College Hospital

Phase EARLY_PHASE1 Recruiting
15 enrolled

FAP- Expressing Positive Tumors

NCT05400967 2024-09-19

Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI

Peking Union Medical College Hospital

Phase EARLY_PHASE1 Recruiting
10 enrolled

177Lu-EB-FAPI

Data powered by HemOnc (CC BY 4.0) Colophon âš¡